GH Research (NASDAQ:GHRS) Trading Down 1.7% – Should You Sell?

GH Research PLC (NASDAQ:GHRS) was down 1.7% during mid-day trading on Thursday . The company traded as low as $10.30 and last traded at $10.76. Approximately 24,391 shares changed hands during trading, a decline of 69% from the average daily volume of 79,513 shares. The stock had previously closed at $10.95.

Analyst Ratings Changes

A number of analysts have recently issued reports on GHRS shares. JMP Securities reaffirmed a “market outperform” rating and set a $39.00 price objective on shares of GH Research in a report on Wednesday, September 4th. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of GH Research in a research report on Wednesday. Finally, Canaccord Genuity Group cut their price target on shares of GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, November 18th.

GH Research Stock Down 3.6 %

The firm’s 50-day simple moving average is $7.91 and its 200-day simple moving average is $10.31. The firm has a market capitalization of $482.32 million, a PE ratio of -11.73 and a beta of 0.74.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.03. On average, equities research analysts forecast that GH Research PLC will post -0.78 earnings per share for the current year.

Hedge Funds Weigh In On GH Research

An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. grew its position in shares of GH Research PLC (NASDAQ:GHRS) by 1.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,686,689 shares of the company’s stock after acquiring an additional 85,000 shares during the period. RA Capital Management L.P. owned about 12.85% of GH Research worth $44,734,000 as of its most recent SEC filing. Institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).